Pharmacokinetics of vancomycin in adult cancer patients

Journal of Oncology Pharmacy Practice

Volumn 16, Issue 4, 2010, Pages 245-250

  Al Kofide, Hadeel ^a   Zaghloul, Iman ^a   Al Naim, Lamya ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

antimicrobial; cancer; pharmacokinetics; therapeutic drug monitoring; vancomycin

Indexed keywords

VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; GRAM POSITIVE INFECTION; HUMAN; POPULATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEADY STATE;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BODY MASS INDEX; DRUG MONITORING; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HALF-LIFE; HUMANS; LEUKEMIA; MALE; MEDICAL RECORDS; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; VANCOMYCIN; YOUNG ADULT;

EID: 78650432401     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155209355847     Document Type: Article

References (28)

1. Maschmeyer G., Haas A. The epidemiology and treatment of infections in cancer patients. Int J Antimicrob Agents 2008 ; 31 (3). 193-7.
2. Karthaus M., Buchheidt D., Hiddemann W., Donnelly JP, Krcmery V., Schiel X. et al. European surveillance of infections in cancer patients - ESIC. Chemotherapy 1999 ; 45: 237-41.
3. Wisplinghoff H., Seifert H., Wenzel RP, Edmond MB Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003 ; 36: 1103-10.
4. Ziglam HM, Gelly K., Olver W. A survey of the management of neutropenic fever in oncology units in the UK. Int J Antimicrob Agents 2007 ; 29 (4). 430-3.
5. Le Normand Y., Milpied N., Kergueris MF, Harousseau JL Pharmacokinetic parameters of vancomycin for therapeutic regimens in neutropenic adult patients. Int J Biomed Comput 1994 ; 36 (1-2). 121-5.
6. Moellering Jr RC Vancomycin: a 50-year reassessment. Clin Infect Dis 2006 ; 42 (suppl 1). S3-4.
7. Stevens DL The role of vancomycin in the treatment paradigm. Clin Infect Dis 2006 ; 42 (suppl 1). S51-7.
8. Rybak M., Lomaestro B., Rotschafer J., Moellering R., Craig W., Billeter M. et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009 ; 66 (1). 82-98.
9. Rybak MJ The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006 ; 42 (suppl 1). S35-9.
10. Rodvold KA, Blum RA, Fischer JH, Zokufa HZ, Rotschafer JC, Crossley KB et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988 ; 32: 848-52.
11. Noonan HM, Elzinga L., Gilbert D., Brummett R., Anderson JL et al. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Clin Pharmacol Ther 1988 ; 43: 565-70.
12. Taylor EH, Olsen KM, Abdel- Malak W., Pappas AA Vancomycin serum protein binding determination by ultrafiltration. Drug Intell Clin Pharm 1988 ; 22: 300-3.
13. Cantú G., Dick D., Elliott E., Humphrey L., Kornhauser DM Protein binding of vancomycin in a patient with immunoglobulin A myeloma. Antimicrob Agents Chemother 1990 ; 34 (7). 1459-61.
14. Begg E., Barclay M., Kirkpatrick C. The therapeutic monitoring of antimicrobial agents. J Clin Pharmacol 2001 ; 52: 35S-43S.
15. Ackerman BH, Vannier AM, Eudy EB Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrob Agents Chemother 1992 ; 36: 1766-9.
16. Löwdin E., Odenholt I., Cars O. In vitro studies of pharmacodynamic properties of vancomycin against staphylococcus aureus and staphylococcus epidermidis. Antimicrob Agents Chemother 1998 ; 42: 2739-44.
17. del Mar Fernández, de Gatta Garcia M., Revilla N., Calvo MV, Domínguez-Gil A., Sánchez Navarro A. Pharmacokinetic/ pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med 2007 ; 33 (2). 279-85.
18. Pea F., Porreca L., Baraldo M., Furlanut M. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 2000 ; 45 (3). 329-35.
19. Rybak MJ, Albrecht LM, Berman JR, Warbasse LH Svensson CK Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother 1990 ; 34: 792-5.
20. Taber DJ, Fann AL, Malat G., Dupuis RE Evaluation of estimated and measured creatinine clearances for predicting the pharmacokinetics of vancomycin in adult liver transplant recipients. Ther Drug Monitor 2003 ; 25 (1). 67-72.
21. Pea F., Poz D., Baraldo M., Furlanut M. Optimisation of vancomycin regimen in neutropenic haematological patients with normal renal function: multiple daily doses may be preferable. Clin Drug Invest 2000 ; 19 (3). 213-8.
22. Fernández de Gatta Mdel M., Fruns M., Hernandez J., Caballero D., San Miguel J., Martinez Lanao J. et al. Vancomycin pharmacokinetics and dosage requirements in hematologic malignancies. Clin Pharm 1993 ; 12: 515-20.
23. Buelga S., del Mar Fernandez M., Herrera V., Dominguez-Gil A., Garcia J. Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies. Antimicrob Agents Chemother 2005 ; 49 (12). 4934-41.
24. Omote S., Yano Y., Hashida T., Masuda S., Yano I., Katsura T. et al. A retrospective analysis of vancomycin pharmacokinetics in Japanese cancer and non-cancer patients based on routine trough monitoring data. Biol Pharm Bull 2009 ; 32 (1). 99-104.
25. Fernández de Gatta Mdel M., Santos Buelga D., Sánchez Navarro A., Dominguez-Gil A., García MJ Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/ pharmacodynamic analysis. Clin Pharmacokinet 2009 ; 48 (4). 273-80.
26. Bertino Jr JS, Booker LA, Franck P., Rybicki B. Gentamicin pharmacokinetics in patients with malignancies. Antimicrob Agents Chemother 1991 ; 35: 1501-03.
27. Davis RL, Lehmann D., Stidley CA, Neidhart J. Amikacin pharmacokinetics in patients receiving high-dose cancer chemotherapy. Antimicrob Agents Chemother 1991 ; 35: 944-7.
28. Zeitany RG, El Saghir NS, Santhosh-Kumar CR, Sigmon MA Increased aminoglycoside dosage requirements in hematologic malignancy. Antimicrob Agents Chemother 1990 ; 34: 702-8.